Letters Ebola virus vaccines

Authors’ reply to Kremer and Van de Perre

BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1308 (Published 10 March 2015) Cite this as: BMJ 2015;350:h1308
  1. Nicholas J Beeching, senior lecturer (honorary consultant)1,
  2. Manuel Fenech, specialist trainee in infectious diseases2,
  3. Catherine F Houlihan, clinical research fellow3
  1. 1Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  2. 2Royal Liverpool University Hospital, Liverpool, UK
  3. 3London School of Hygiene and Tropical Medicine, London, UK
  1. nicholas.beeching{at}rlbuht.nhs.uk

Kremer and Van de Perre highlight important concerns.1 2 HIV incidence was increased mainly in men in the long term follow-up (3.5 years after vaccination) of the Phambili HIV vaccine trial, which used an adenovirus type 5 vectored DNA vaccine.3 The candidate Ebola adenovirus vectored vaccine is of a different adenovirus subtype (type 3).4 5 However, the postulated mechanism of …

View Full Text

Sign in

Log in through your institution

Subscribe